Non-denaturing lysis reagent

ABSTRACT

The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits.

CROSS-REFERENCE TO RELATED APPLICATIONS

Not applicable.

FIELD OF THE INVENTION

This invention relates to a non-denaturing lysis reagent useful, forexample, in diagnostic immunoassays to determine the concentrationlevels of an immunosuppressant drug in a test sample.

BACKGROUND OF THE INVENTION

Many analytes of clinical interest are taken up by cells or becomecomplexed with one or more other components of the test sample.Accordingly, to obtain an accurate measurement of the amount of analytepresent in the sample, it is preferable to treat the sample, and/orconduct the assay under conditions, such that the analyte is releasedfrom the cells or other component(s) for detection in the assay.

For example, immunosuppressant drugs such as tacrolimus, everolimus,temsorolimus and cyclosporine are effective for the treatment of organor tissue rejection following transplant surgery, of graft versus hostdisease and of autoimmune diseases in humans. During immunosuppressantdrug therapy, monitoring the blood concentration levels of theimmunosuppressant is an important aspect of clinical care becauseinsufficient drug levels lead to graft (organ or tissue) rejection andexcessive levels lead to undesired side effects and toxicities. Bloodlevels of immunosuppressant are therefore measured so drug dosages canbe adjusted to maintain the drug level at the appropriate concentration.Diagnostic assays for determination of immunosuppressant blood levelshave thus found wide clinical use.

Initially, the immunosuppressant must be extracted and separated fromthe other components of the patient sample. The bulk of theimmunosuppressant drug in the patient sample is present in a complexwith various “carrier” molecules, such as binding proteins. Sirolimus,tacrolimus and cyclosporine are found predominately in the red bloodcells of patient specimens and are associated with specific bindingproteins, FKBP for sirolimus and tacrolimus, and cyclophilin forcyclosporine. To ensure an accurate measurement of the total drugconcentration in the specimen, the drug bound to the binding proteins ispreferably liberated prior to quantitation. This has been addressed byusing detergents to lyse cells and/or organic solvents to denature thesample proteins.

Following its extraction from the binding proteins, the drug can bemeasured in a number of different ways, including by immunoassay orchromatography with absorbance or mass spectrophotometric detection.Immunoassays for immunosuppressant drugs are available in a variety offormats, but all use the binding of an antibody or binding protein (e.g.FKBP) to the immunosuppressant drug. A commonly used immunoassay is anassay which involves the binding of a first antibody to theimmunosuppressant and the binding of labeled immunosuppressant (e.g.acridinium-sirolimus) to the remaining free antibody binding sites,followed by quantitation by detection of the label.

SUMMARY OF THE INVENTION

The invention provides a method for preparing a test sample for use inan assay, the method comprising contacting the test sample with a lysisreagent to form a lysis mixture. The lysis reagent includes a glycolselected from the group consisting of ethylene glycol, propylene glycol,and an analog thereof, and at least one alcohol having five or fewercarbons is included in the lysis reagent or added to the lysis mixture.The alcohol can, for example, be methanol, ethanol, and/or propanol. Inparticular embodiments, the test sample includes a human blood sample.

Advantages of the sample preparation method of the invention includethat the sample can be prepared for analysis without a centrifugationstep and/or without the use of a detergent.

In preferred embodiments, the alcohol is included in the lysis reagent.In variations of such embodiments, the ratio of glycol to alcohol is inthe range of about 4:1 to about 1:4 or, preferably, about 4:1 to about1:2. The test sample can be added to any such lysis reagent at a ratioin the range of about 2:1 to about 1:2.

Where the method is carried out to prior to an assay for an analyte thatis bound to one or more binding proteins in the test sample, the methodcan additionally include contacting the test sample or the lysis mixturewith an agent that releases the analyte from the binding protein(s). Thereleasing agent can, for example, be an agent that competes with theanalyte for binding to the binding protein(s). In an exemplaryembodiment, the analyte includes an immunosuppressant drug, and theagent includes a different, but structurally similar, immunosuppressantdrug. Where the analyte includes a non-protein molecule, the agent can,for example, include a protease that degrades the binding protein(s).

Another aspect of the invention is a lysis reagent mixture, whichincludes a glycol selected from the group consisting of ethylene glycol,propylene glycol, and an analog thereof and at least one alcohol havingfive or fewer carbons. In exemplary embodiments, the ratio of glycol toalcohol is in the range of about 4:1 to about 1:4 or, preferably, about4:1 to about 1:2. This glycol-alcohol mixture is typically added to atest sample, in exemplary embodiments, at a ratio in the range of about2:1 to about 1:2. Accordingly, the term “lysis reagent mixture” alsoincludes the mixture that results from the addition of theglycol-alcohol mixture to the test sample. The alcohol can, for example,be methanol, ethanol, and/or propanol. In particular embodiments, thetest sample includes a human blood sample.

The invention also provides a method for assessing the presence orconcentration of an analyte in a test sample. This method entailscontacting the test sample with a lysis reagent to form a lysis mixtureand assaying the lysis mixture for the analyte. The lysis reagentincludes a glycol selected from the group consisting of ethylene glycol,propylene glycol, and an analog thereof, and at least one alcohol havingfive or fewer carbons is included in the lysis reagent or added to thelysis mixture. The alcohol can, for example, be methanol, ethanol,and/or propanol. In particular embodiments, the test sample includes ahuman blood sample.

In exemplary embodiments, the alcohol is included in the lysis reagent,and the ratio of glycol to alcohol is in the range of about 4:1 to about1:4 or, preferably, about 4:1 to about 1:2. This glycol-alcohol mixtureis typically added to a test sample, in exemplary embodiments, at aratio in the range of about 2:1 to about 1:2.

Advantages of the sample preparation method of the invention includethat the lysis mixture is a homogeneous mixture, suitable for automatedpipetting, without the need for a centrifugation step and/or without theuse of a detergent. However, the test sample or the lysis mixture can becontacted with a detergent, if desired.

The lysis mixture can, for example, be analyzed by immunoassay. Inexemplary embodiments, the analyte detected includes animmunosuppressant drug, such as, for example, sirolimus, tacrolimus,everolimus, temsorolimus, zotarolimus, cyclosporine, or analogs of anyof these compounds.

In particular embodiments, the assay detects an analyte that is bound toone or more binding proteins in the test sample. In such embodiments,the method can additionally include contacting the test sample or thelysis mixture with an agent that releases the analyte from the bindingprotein(s). The releasing agent can, for example, be an agent thatcompetes with the analyte for binding to the binding protein(s). In anexemplary embodiment, the analyte includes an immunosuppressant drug,and the agent includes a different, but structurally similar,immunosuppressant drug. Where the analyte includes a non-proteinmolecule, the agent can, for example, include a protease that degradesthe binding protein(s).

Another aspect of the invention is a test kit including: (a) at leastone antibody or protein capable of binding specifically to at least oneanalyte; (b) a lysis reagent including a glycol selected from the groupconsisting of ethylene glycol, propylene glycol, and an analog thereof;and (c) at least one alcohol having five or fewer carbons. The alcoholcan, for example, be methanol, ethanol, and/or propanol. In preferredembodiments, the lysis reagent and alcohol(s) are combined and packagedin a single container. In variations of such embodiments, the ratio ofglycol to alcohol is in the range of about 4:1 to about 1:4, preferablyabout 4:1 to about 1:2. The test kit can, optionally, contain a controlcomposition including the at least one analyte of (a) and/or adetergent.

In exemplary embodiments, the analyte detected includes animmunosuppressant drug, such as, for example, sirolimus, tacrolimus,everolimus, temsorolimus, zotarolimus, cyclosporine, or analogs of anyof these compounds.

In particular embodiments, the test kit additionally includes an agentthat releases the analyte from one or more binding proteins in the testsample. The releasing agent can, for example, be an agent that competeswith the analyte for binding to the binding protein(s). In an exemplaryembodiment, the analyte includes an immunosuppressant drug, and theagent includes a different, but structurally similar, immunosuppressantdrug. Where the analyte includes a non-protein molecule, the agent can,for example, include a protease that degrades the binding protein(s).

An exemplary, preferred test kit according to the invention includes:(a) at least one antibody or protein capable of binding specifically toat least one immunosuppressant drug selected from the group consistingof sirolimus, tacrolimus, everolimus, temsorolimus, zotarolimus andcyclosporine; (b) a lysis reagent including propylene glycol and ethanolat a ratio in the range of about 4:1 to about 1:2; and (c) controlcomposition including the at least one immunosuppressant drug of (a).

DETAILED DESCRIPTION

The invention relates to a non-denaturing lysis reagent that can bemixed with a test sample to produce a homogenous lysis mixture. Thisapproach is superior to previous extraction methods that rely on the useof detergents or denaturants.

The use of detergents can be problematic, in particular formats becausethe quantity of detergent needed to quickly lyse and fragment cells maycause foaming, which is unacceptable for samples that must be pipettedby most automated pipetting systems, and may interfere withimmunochemistry in samples to be analyzed immunoassay. The lysis reagentof the invention produces a sample that is not susceptible to foamingand eliminates the need for detergents, thus avoiding detergent driveninterferences in assay immunochemistry.

The use of denaturants requires subsequent centrifugation steps toremove precipitated blood constituents, which reduces the efficiency ofthis approach. Additionally, the use of organic solvents at theconcentration required can lead to sample evaporation that issignificant enough to affect analyte concentration. The lysis reagent ofthe invention produces a homogeneous mixture that is suitable for use inautomated pipetting systems without the need for a centrifugation stepand eliminates the use of substantial concentrations of volatile organicsolvents.

DEFINITIONS

Terms used in the claims and specification are defined as set forthbelow unless otherwise specified.

An “immunosuppressant drug” or “immunosuppressant”, as used herein,refers to a therapeutic compound, either small molecule or antibodybased, that has the same or similar chemical structure to eitherrapamycin (sirolimus) or cyclosporine, also known as cyclosporine A. Anyknown or hereafter developed analog of either rapamycin or cyclosporineis considered an immunosuppressant herein. Preferred immunosuppressantsinclude sirolimus, tacrolimus, everolimus, temsorolimus, zotarolimus andcyclosporine. Tacrolimus and cyclosporine are calcineurin inhibitorsthat suppress early activation of the immune system's T lymphocytesthrough inhibition of cytokines such as interleukin 2. In contrast, theprimary target of sirolimus, everolimus and zotarolimus is mammaliantarget of rapamycin (mTOR), a specific cell-cycle regulatory protein.The inhibition of mTOR leads to suppression of cytokine-drivenT-lymphocyte proliferation.

The chemical formula of cyclosporine is in Formula A. The chemicalformula of sirolimus (rapamycin) is in Formula B. The chemical formulaof the structural difference of everolimus (RAD) from sirolimus is inFormula C.

Numerous derivatives or analogs of cyclosporine have been prepared. Theinvention comprises lysis reagents, lysis methods, assays and assay kitsfor cyclosporine or any of its analogs.

Numerous derivatives or analogs of rapamycin have been prepared. Forexample, these include the preparation of ester mono- and di-esterderivatives of rapamycin (WO 92/05179), 27-oximes of rapamycin (EPO467606); 42-oxo analog of rapamycin (U.S. Pat. No. 5,023,262); bicyclicrapamycins (U.S. Pat. No. 5,120,725); rapamycin dimers (U.S. Pat. No.5,120,727); sayl ethers of rapamycin (U.S. Pat. No. 5,120,842); andarylsulfonates and sulfamates (U.S. Pat. No. 5,177,203). Rapamycin wasrecently synthesized in its naturally occurring enantiomeric form (K. C.Nicolaou et al., J. Am. Chem. Soc., 1993, 115, 4419-4420; S. L.Schreiber, J. Am. Chem. Soc., 1993, 115, 7906-7907; S. J. Danishefsky,J. Am. Chem. Soc., 1993, 115, 9345-9346. The invention comprises lysisreagents, lysis methods, assays and assay kits for rapamycin or any ofits analogs.

Another immunosuppressant analog of rapamycin is FK-506, also known astacrolimus, which was isolated from a strain of S. tsukubaensis.FK-506's chemical formula is published in European Patent EP 0 293 892B1. Analogs of FK-506 include the related natural products FR-900520 andFR-900523, which differ from FK-506 in their alkyl substituent at C-21,and were isolated from S. hygroscopicus yakushimnaensis. Another analog,FR-900525, produced by S. tsukubaensis, differs from FK-506 in thereplacement of a pipecolic acid moiety with a proline group. Theinvention comprises lysis reagents, lysis methods, assays and assay kitsfor FK-506 or any of its analogs. Temsorolimus is another esterderivative of sirolimus which can be monitored with the invention.

ABT-578 [40-epi-(1-tetrazolyl)-rapamycin], known better today aszotarolimus, is a semi-synthetic macrolide triene antibiotic derivedfrom rapamycin. Zotarolimus structure is shown in Formula D.

As used herein with reference to an immunosuppressant drugs, the term“structurally similar” indicates that the drugs have sufficientlysimilar structures that the drugs bind competitively to at least onecommon binding partner (e.g., a binding protein).

The term “test sample” refers to a component, tissue or fluid of ananimal's body that is the source of the immunosuppressant drug analyte.These components, tissues and fluids include human and animal bodyfluids such as whole blood, serum, plasma, synovial fluid, cerebrospinalfluid, urine, lymph fluids, and various external secretions of therespiratory, intestinal and genitorurinary tracts, tears, saliva, milk,white blood cells, myelomas and the like; biological fluids such as cellculture supernatants; fixed tissue specimens; and fixed cell specimens.Preferably, the test sample is a human peripheral blood sample.

As used herein, an “antibody” refers to a protein consisting of one ormore polypeptides substantially encoded by immunoglobulin genes orfragments of immunoglobulin genes. This term encompasses polyclonalantibodies, monoclonal antibodies, and fragments thereof, as well asmolecules engineered from immunoglobulin gene sequences. The recognizedimmunoglobulin genes include the kappa, lambda, alpha, gamma, delta,epsilon and mu constant region genes, as well as myriad immunoglobulinvariable region genes. Light chains are classified as either kappa orlambda. Heavy chains are classified as gamma, mu, alpha, delta, orepsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA,IgD and IgE, respectively.

A typical immunoglobulin (antibody) structural unit is known to comprisea tetramer. Each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (about 25 kD) and one“heavy” chain (about 50-70 kD). The N-terminus of each chain defines avariable region of about 100 to 110 or more amino acids primarilyresponsible for antigen recognition. The terms “variable light chain(VL)” and “variable heavy chain (VH)” refer to these light and heavychains respectively.

Antibodies exist as intact immunoglobulins or as a number ofwell-characterized fragments produced by digestion with variouspeptidases. Thus, for example, pepsin digests an antibody below thedisulfide linkages in the hinge region to produce F(ab′)2, a dimer ofFab which itself is a light chain joined to VH-CHI by a disulfide bond.The F(ab′)2 may be reduced under mild conditions to break the disulfidelinkage in the hinge region thereby converting the (Fab′)2 dimer into aFab′ monomer. The Fab′ monomer is essentially a Fab with part of thehinge region (see, Fundamental Immunology, W. E. Paul, ed., Raven Press,N.Y. (1993), for a more detailed description of other antibodyfragments). While various antibody fragments are defined in terms of thedigestion of an intact antibody, one of skill will appreciate that suchFab′ fragments may be synthesized de novo either chemically or byutilizing recombinant DNA methodology.

Thus, the term “antibody,” as used herein, also includes antibodyfragments either produced by the modification of whole antibodies orsynthesized de novo using recombinant DNA methodologies. The term“antibody” also encompasses single chain antibodies (antibodies thatexist as a single polypeptide chain), more preferably single chain Fvantibodies (sFv or scFv), in which a variable heavy and a variable lightchain are joined together (directly or through a peptide linker) to forma continuous polypeptide. The single chain Fv antibody is a covalentlylinked VH-VL heterodimer which may be expressed from a nucleic acidincluding VH- and VL-encoding sequences either joined directly or joinedby a peptide-encoding linker. Huston, et al. (1988) Proc. Nat. Acad.Sci. USA, 85: 5879-5883. While the VH and VL are connected to each as asingle polypeptide chain, the VH and VL domains associatenon-covalently. The scFv antibodies and a number of other structuresconverting the naturally aggregated, but chemically separated, light andheavy polypeptide chains from an antibody V region into a molecule thatfolds into a three dimensional structure substantially similar to thestructure of an antigen-binding site are known to those of skill in theart (see e.g., U.S. Pat. Nos. 5,091,513, 5,132,405, and 4,956,778).

“Analyte,” as used herein, refers to the substance to be detected, whichmay be present in the test sample. The analyte can be any substance forwhich there exists a naturally occurring specific binding partner or forwhich a specific binding partner can be prepared. Thus, an analyte is asubstance that can bind to one or more specific binding partners in anassay.

A “binding partner,” as used herein, is a member of a binding pair,i.e., a pair of molecules wherein one of the molecules binds to thesecond molecule. Binding partners that bind specifically are termed“specific binding partners.” In addition to the antigen and antibodybinding partners commonly used in immunoassays, other specific bindingpartners can include biotin and avidin, carbohydrates and lectins,complementary nucleotide sequences, effector and receptor molecules,cofactors and enzymes, enzyme inhibitors and enzymes, and the like.Immunoreactive specific binding partners include antigens, antigenfragments, antibodies and antibody fragments, both monoclonal andpolyclonal, and complexes thereof, including those formed by recombinantDNA methods.

The term “specific binding” is defined herein as the preferentialbinding of binding partners to another (e.g., a polypeptide and a ligand(analyte), two polypeptides, a polypeptide and nucleic acid molecule, ortwo nucleic acid molecules) at specific sites. The term “specificallybinds” indicates that the binding preference (e.g., affinity) for thetarget molecule/sequence is at least 2-fold, more preferably at least5-fold, and most preferably at least 10- or 20-fold over a non-specifictarget molecule (e.g. a randomly generated molecule lacking thespecifically recognized site(s)).

An antibody that specifically binds an immunosuppressant drug is said tobe “specific for” that immunosuppressant drug.

The term “capture agent” is used herein to refer to a binding partnerthat binds to analyte, preferably specifically. Capture agents can beattached to a solid phase. As used herein, the binding of a solidphase-affixed capture agent to analyte forms a “solid phase-affixedcomplex.”

The term “labeled detection agent” is used herein to refer to a bindingpartner that binds to analyte, preferably specifically, and is labeledwith a detectable label or becomes labeled with a detectable labelduring use in an assay.

A “detectable label” includes a moiety that is detectable or that can berendered detectable.

As used with reference to a labeled detection agent, a “direct label” isa detectable label that is attached, by any means, to the detectionagent.

As used with reference to a labeled detection agent, an “indirect label”is a detectable label that specifically binds the detection agent. Thus,an indirect label includes a moiety that is the specific binding partnerof a moiety of the detection agent. Biotin and avidin are examples ofsuch moieties that are employed, for example, by contacting abiotinylated antibody with labeled avidin to produce an indirectlylabeled antibody.

As used herein, the term “indicator reagent” refers to any agent that iscontacted with a label to produce a detectable signal. Thus, forexample, in conventional enzyme labelling, an antibody labeled with anenzyme can be contacted with a substrate (the indicator reagent) toproduce a detectable signal, such as a colored reaction product.

As used herein, a “glycol analog” is any glycol having from two to sixcarbon atoms.

A lysis mixture is said to be “homogenous” when it is sufficiently freeof large particulates to allow accurate and reliable pipetting (eithermanually or using an automated system).

I. Sample Collection and Processing

The methods of the invention are generally carried out on test samplesderived from an animal, preferably a mammal, and more preferably ahuman.

The methods of the invention can be carried out using any sample thatmay contain the analyte of interest (e.g., an immunosuppressant drug),such as a blood sample.

The sample is collected by any standard technique and then contactedwith a lysis reagent to form a lysis mixture. The lysis reagent includesa glycol having from two to six carbon atoms. At least one alcoholhaving five or fewer carbons is included in the lysis reagent or addedto the lysis mixture. In preferred embodiments, the lysis reagentincludes the alcohol(s). Glycols suitable for use in the lysis reagentincude, for example, ethylene glycol, propylene glycol, and analogsthereof thereof, as well as mixtures of such glycols. Alcohols suitablefor use in the invention include, for example, methanol, ethanol,propanol, and mixtures thereof. In particular embodiments, the ratio ofglycol to alcohol is in the range of about 5:1 to about 1:5, 4:1 toabout 1:4, 2:1 to about 1:2, or about 1:1 (volume:volume). In moreparticular embodiments, the ratio of glycol to alcohol is in the rangeof about 4:1 to about 1:2.

The lysis mixture can formed by any mixing technique at any desirabletemperature to contact any chosen amount of the sample with the lysisreagent. The sample is contacted with a sufficient volume of lysisreagent to lyse the cells in the sample and produce a homogeneousmixture. For a lysis reagent wherein the ratio of glycol to alcohol isin the range of about 4:1 to about 1:4, as described above, sample canbe added to the lysis reagent at a ratio in the range of about 2:1 toabout 1:2, about 1:3, about 1:4, about 1:5, or about 1:10; e.g., about1:1 (volume:volume), or any other range including these values asendpoints, depending on the lysis reagent composition. For example,about 100 uL to about 600 uL of blood sample can be mixed with about 50uL to about 1200 uL of the lysis reagent for up to about five minutes.In certain embodiments, the lysis mixture is formed by mixing 150 uL ofblood sample with 300 uL of lysis reagent and vortexing vigorously for5-10 seconds. In preferred embodiments, lysis is complete in less than aminute at room temperature. The lysis mixture is then assayed for theanalyte using a suitable assay. In preferred embodiments, the lysismixture is produced, ready for analysis, without the need to centrifugethe sample.

The lysis reagent of the invention can be employed without any addeddetergent. However, in certain embodiments, one or more detergents canbe added, if desired. Detergents typically do not foam in the presenceof the lysis reagent, and thus lysis mixtures prepared according to theinvention are amenable to automated pipetting, regardless of whether adetergent is included. If included in a lysis mixture intended forimmunoassay, the detergent is preferably present at a concentration thatdoes not interfere with the immunochemistry. Preferably, the detergentis a non-ionic detergent, such as saponin, and is employed at aconcentration in the range of about 0.01% to 0.1%, more preferably about0.1%. U.S. Pat. No. 5,650,288 (issued Jul. 22, 1997 to MacFarlane andJensen; hereby incorporated by reference in its entirety) describes theuse of detergents and in immunoassays for immunosuppressants.

In particular embodiments, where the analyte is bound to one or morebinding proteins in the test sample, the method can additionally entailcontacting the test sample with an agent that releases the analyte fromthe binding protein(s). This agent can be included in the lysis reagent,if desired. The agent can, for example, be one that competes with theanalyte for binding to the binding protein(s). The agent is generallyselected so that it will not affect the results of the assay to becarried out. Thus, for instance, if the assay is an immunoassay, theagent is typically one that the relevant antibody does not cross-reactwith. Where the analyte is an immunosuppressant drug, the agent can be adifferent, but structurally similar, immunosuppressant drug. Forexample, sirolimus and tacrolimus both bind FKBP, and, for this reason,sirolimus can be used to release tacrolimus from FKBP and vice versa.Any subsequent immunoassay will generally employ an antibody thatdistinguishes between sirolimus and tacrolimus. U.S. Pat. No. 6,187,547(issued Feb. 13, 2001 to Legay and Wenger; incorporated herein byreference in its entirety) describes “binding competitors” useful forreleasing immunosuppressant drugs from binding proteins. Examplesinclude: [Thr², Leu⁵, D-Hiv⁸, Leu¹⁰]-Ciclosporin, which can releasecyclosporine.

Where the analyte is a non-protein molecule, a protease can be employedto release the analyte from binding protein(s). The protease used in themethod should be one that can degrade the binding protein, therebyreleasing the analyte for assay and can be inactivated without adverselyaffecting the sensitivity and the precision of the assay to be carriedout. Care should be taken in obtaining enzymes free from othercontaminating enzymes that might not be inactivated by the method ofinactivation used. Otherwise, any residual proteolytic activity coulddegrade an antibody used in a subsequent immunoassay. Exemplaryproteases include proteinase K, subtilisin, dispase, thermolysin,trypsin, ficin, bromelain, and combinations thereof.

Proteinase K (Sigma Chemical Co., St. Louis, Mo.) is a nonspecific,Ca-dependent protease that can be inactivated by heat (65° C. or higher)and by specific protease inhibitors, such as phenyl methyl sulfonylfluoride (PMSF, Boehringer Mannheim, Indianapolis, Ind.) ordiisopropylfluorophosphate (DFP, Calbiochem, La Jolla, Calif.).Subtilisin (Sigma) is also a nonspecific, Ca-dependent protease that canbe inactivated by heat (55° C. or higher), although it can be inhibitedby acidic pH or a specific protease inhibitor, such as PMSF, DFP oraprotinin.

Dispase (Boehringer Mannheim or Sigma or Calbiochem) and thermolysin(Sigma or Boehringer Mannheim) are Ca-dependent metallo-proteases, whichcan be inactivated by EDTA, at a concentration of about 5 mM, forexample. When dispase and thermolysin combined are used as the protease,proteolysis is preferably inactivated by addition of a divalent cationchelator, such as EDTA, at a concentration of about 5 mM, for example,in the presence of a zinc salt, e.g., ZnSO₄, at a concentration of about40 mM, for example.

Trypsin (Worthingtom Enzymes, Freehold, N.J.) cleaves proteinsspecifically at the carboxyl side of lysine or arginine residues and canbe inhibited by heat (90° C. or higher) or specifically inhibited bymany agents, including aprotinin (Trasylol, Miles, Kankakee, Ill. orCalbiochem), leupeptin (Sigma or Boehringer Mannheim), PMSF, or specifictrypsin inhibitors derived from soybean, lima bean or egg white(Worthington or Sigma). Ficin is a thiol protease that can beinactivated by HgCl₂, at a concentration of about 2 mM, for example.Bromelain is also a thiol protease and can be inactivated by bromelaininhibitor (Sigma).

In particular embodiments, the concentration of protease is high enoughto degrade to the binding proteins within about 30 min, preferablywithin about 20 min, yet low enough to allow efficient inactivation ofthe enzyme. Accordingly, the concentration of protease is preferably bein the range of about 0.5 to 2.0 units/ml, more preferably about 1unit/ml.

After lysis and release from binding proteins, if applicable, theanalyte can be measured using any standard technique for detecting thatanalyte, e.g., immunoassay or chromatography with absorbance or massspectrophotometric detection. For detection of immunosuppressant drugs,immunoassays are conveniently employed.

II. Immunoassays

A. In General

Immunoassays according to the invention can be used for the qualitativeidentification and/or the quantification of analyte in a test sample.These methods are applicable, for example, to immunoassays ofimmunosuppressant drugs, such as rapamycin (sirolimus), tacrolimus,everolimus, temsorolimus, zotarolimus, cyclosporine, and analogs of anyof these compounds. Such immunoassays can be carried out by combining alysis reagent with the test sample to form a lysis mixture, as describedabove. The lysis mixture can be contacted with at least one antibodyspecific for the analyte under conditions suitable for binding of theantibody to the analyte, if present, to form an assay mixture, andbinding of the antibody to the analyte is then detected.

In certain embodiments, enhanced assay sensitivity can be achieved bycontacting the lysis mixture with the antibody in the presence of a saltconcentration of greater than about 0.4 M. In particular embodiments,the salt concentration is less than or equal to about 4.0 M. Inexemplary embodiments, the salt concentration is about 2.0 M. Suitablesalts can include, for example, any of the following anions: fluoride,chloride, bromide, iodide, thiocyanate, acetate, citrate, and bisulfate.In particular embodiments, the salt includes a monovalent anion, suchas, for example: fluoride, chloride, bromide, iodide, thiocyanate, andacetate. In preferred embodiments, the salt includes chloride, e.g., achloride salt of an alkalai metal (e.g., lithium, sodium, potassium,rubidium, cesium). Generally, the salt employed is soluble under theassay conditions. Sodium chloride is highly soluble under mostconditions, and can thus be conveniently used to enhance assaysensitivity in a wide variety of immunoassays according to theinvention.

The salt can be provided to the assay mixture in any convenient mannerand can be present before, or added after, contact between the lysismixture and the antibody. In particular embodiments, the salt isprovided in an assay diluent, which can also optionally include one ormore other components, in addition to water (such as, for example, abuffer). The salt concentration in the assay diluent will vary,depending on the desired final salt concentration and on the amount ofdiluent added to the assay mixture. For example, an assay diluent havinga salt concentration of about 4.0 M could be added to an equal volume ofassay mixture to provide a final salt concentration of 2.0 M.

B. Antibodies

In immunoassays for the qualitative or quantitative detection of ananalyte in a test sample, at least one antibody that binds to theanalyte is contacted with a lysis mixture suspected of containing theanalyte to form an antibody-analyte immune complex. To detectimmunosuppressant drugs, any suitable antibodies that bind to theparticular drug can be used in immunoassay according to the invention.Antibodies to each of rapamycin (sirolimus), tacrolimus, zotarolimus,cyclosporine and everolimus are known in the art, and any of these canbe used. It is preferred to use the monoclonal antibody that is acomponent of Abbott Laboratories' commercially available 1M Sirolimusassay for measuring sirolimus.

An exemplary protocol for producing an antibody specific for animmunosuppressant drug is as follows. Female RBf/Dnj mice areadministered 3 monthly boosts of a drug-27-CMO-tetanus toxoid immunogenfollowed by an immunization with drug-42-HS-tetanus toxoid preparationon the 4th month. Seven months later, an intrasplenic pre-fusion boostis administered to the animal using the drug-27-CMO-tetanus toxoidimmunogen 3 days prior to the fusion. Splenic B-cells are then isolatedand used in a standard polyethylene (PEG) fusion with the SP2/0 myeloma.Confluent cultures are screened for anti-drug activity 10-14 days laterin a microtiter EIA and positive cultures are then cloned using limitingdilution cloning technique. The resulting clones are isolated and scaledup in IMDM w/FBS (Invitrogen) tissue culture medium and the secretedantibody is affinity purified using Protein A. An exemplary, preferredantibody generated using sirolimus as the drug can be used inimmunoassays for sirolimus, everolimus and zotarolimus.

An exemplary, preferred antibody for use in immunoassays for tacrolimusis described in M. Kobayashi et al., “A Highly Sensitive Method to AssayFK-506 Levels in Plasma”, at pp 23-29 of “FK-506 A PotentialBreakthrough in Immunosuppression”, A Transplantation ProceedingsReprint, Supplement 6, Vol. XIX, October, 1987, Editors T. Starzl, L.Makowka and S. Todo, published by Grune & Stratton, Inc., Philadelphia,Pa.

An exemplary, preferred antibody for use in immunoassays forcyclosporine is the monoclonal antibody that is a component of AbbottLaboratories' commercially available AxSYM cyclosporine assay formeasuring cyclosporine.

C. Detection

The antibody-analyte immune complexes can then detected using anysuitable technique. For example, an antibody can be labeled with adetectable label to detect the presence of the antibody-analyte complex.The selection of a particular label is not critical, but the chosenlabel must be capable of producing a detectable signal either by itselfor in conjunction with one or more additional substances.

Useful detectable labels, their attachment to antibodies and detectiontechniques therefor are known in the art. Any detectable label known inthe art can be used. For example, the detectable label can be aradioactive label, such as, ³H, ¹²⁵I, ³⁵S, ¹⁴C, ³²P, ³³P; an enzymaticlabel, such as horseradish peroxidase, alkaline peroxidase, glucose6-phosphate dehydrogenase, etc.; a chemiluminescent label, such as,acridinium derivatives, luminol, isoluminol, thioesters, sulfonamides,phenanthridinium esters, etc.; a fluorescent label, such as, fluorescein(5-fluorescein, 6-carboxyfluorescein, 3′6-carboxyfluorescein,5(6)-carboxyfluorescein, 6-hexachloro-fluorescein,6-tetrachlorofluorescein, fluorescein isothiocyanate, etc.), rhodamine,phycobiliproteins, R-phycoerythrin, quantum dots (zinc sulfide-cappedcadmium selenide), a thermometric label or an immuno-polymerase chainreaction label. An introduction to labels, labeling procedures anddetection of labels is found in Polak and Van Noorden, Introduction toImmunocytochemistry, 2^(nd) ed., Springer Verlag, N.Y.(1997) and inHaugland, Handbook of Fluorescent Probes and Research Chemi (1996),which is a combined handbook and catalogue published by MolecularProbes, Inc., Eugene, Oreg., each of which is incorporated herein byreference. Preferred labels for use with the invention arechemiluminscent labels such as acridinium-9-carboxamide. Additionaldetail can be found in Mattingly, P. G., and Adamczyk, M. (2002)Chemiluminescent N-sulfonylacridinium-9-carboxamides and theirapplication in clinical assays, in Luminescence Biotechnology:Instruments and Applications (Dyke, K. V., Ed.) pp 77-105, CRC Press,Boca Raton.

The detectable label can be bound to the analyte, analyte analog, orantibody either directly or through a coupling agent. An example of acoupling agent that can be used is EDAC(1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, hydrochloride), whichis commercially available from Sigma-Aldrich (St. Louis, Mo.). Othercoupling agents that can be used are known in the art. Methods forbinding a detectable label to an antibody are known in the art.Additionally, many detectable labels can be purchased or synthesizedthat already contain end groups that facilitate the coupling of thedetectable label to the antibody, such as,N10-(3-sulfopropyl)-N-(3-carboxypropyl)-acridinium-9-carboxamide,otherwise known as CPSP-Acridinium Ester orN10-(3-sulfopropyl)-N-(3-sulfopropyl)-acridinium-9-carboxamide,otherwise known as SPSP-Acridinium Ester.

Alternatively, a second antibody that binds to analyte and that containsa detectable label can be added to the lysis mixture and used to detectthe presence of the antibody-analyte complex. Any suitable detectablelabel can be used in this embodiment.

D. Exemplary Formats

The immunoassays of the invention can be conducted using any formatknown in the art, such as, but not limited to, a sandwich format, acompetitive inhibition format (including both forward or reversecompetitive inhibition assays) or a fluorescence polarization format.The exemplary formats described below are described in terms of assayingan immunosuppressant drug. However, as those of skill in the artappreciate, the described formats are applicable to any analyte.

In immunoassays for the quantitative detection of an immunosuppressant,such as a preferred sandwich type format, at least two antibodies areemployed to separate and quantify the drug in the lysis mixture. Morespecifically, the at least two antibodies bind to different parts of thedrug, forming an immune complex which is referred to as a “sandwich”.Generally, one or more antibodies can be used to capture theimmunosuppressant in the test sample (these antibodies are frequentlyreferred to as a “capture” antibody or “capture” antibodies) and one ormore antibodies is used to bind a detectable (namely, quantifiable)label to the sandwich (these antibodies are frequently referred to asthe “detection” antibody or “detection” antibodies). In a sandwichassay, it is preferred that both antibodies binding to the drug are notdiminished by the binding of any other antibody in the assay to itsrespective binding site. In other words, antibodies should be selectedso that the one or more first antibodies brought into contact with alysis mixture suspected of containing an immunosuppressant do not bindto all or part of the binding site recognized by the second orsubsequent antibodies, thereby interfering with the ability of the oneor more second or subsequent antibodies to bind to the drug. In asandwich assay, the antibodies, and preferably, the at least one captureantibody, are used in molar excess amounts relative to the maximumamount of drug expected in the lysis mixture. For example, from about 5μg/mL to about 1 mg/mL of antibody per mL of solid phase containingsolution can be used.

In one embodiment, the at least one first capture antibody can be boundto a solid support which facilitates the separation of the firstantibody-drug complex from the test sample. The solid support or “solidphase” used in the inventive immunoassay is not critical and can beselected by one skilled in the art. A solid phase or solid support, asused herein, refers to any material that is insoluble, or can be madeinsoluble by a subsequent reaction. Useful solid phases or solidsupports are known to those in the art and include the walls of wells ofa reaction tray, test tubes, polystyrene beads, magnetic beads,nitrocellulose strips, membranes, microparticles such as latexparticles, sheep (or other animal) red blood cells, and Duracytes® (aregistered trademark of Abbott Laboratories, Abbott Park, Ill.), whichare red blood cells “fixed” by pyruvic aldehyde and formaldehyde, andothers. Suitable methods for immobilizing peptides on solid phasesinclude ionic, hydrophobic, covalent interactions and the like. Thesolid phase can be chosen for its intrinsic ability to attract andimmobilize the capture agent. Alternatively, the solid phase cancomprise an additional receptor which has the ability to attract andimmobilize the capture agent. The additional receptor can include acharged substance that is oppositely charged with respect to the captureagent itself or to a charged substance conjugated to the capture agent.As yet another alternative, the receptor can be any specific bindingpartner which is immobilized upon (attached to) the solid phase andwhich has the ability to immobilize the capture agent through a specificbinding reaction. The receptor molecule enables the indirect binding ofthe capture agent to a solid phase material before the performance ofthe assay or during the performance of the assay.

Any solid support known in the art can be used, including but notlimited to, solid supports made out of polymeric materials in the formsof wells, tubes or beads. The antibody (or antibodies) can be bound tothe solid support by adsorption, by covalent bonding using a chemicalcoupling agent or by other means known in the art, provided that suchbinding does not interfere with the ability of the antibody to bind thedrug. Moreover, if necessary, the solid support can be derivatized toallow reactivity with various functional groups on the antibody. Suchderivatization requires the use of certain coupling agents such as, butnot limited to, maleic anhydride, N-hydroxysuccinimide and1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.

It is within the scope of the present invention that the solid phasealso can comprise any suitable porous material with sufficient porosityto allow access by detection antibodies and a suitable surface affinityto bind antigens. Microporous structure generally are preferred, butmaterials with gel structure in the hydrated state may be used as well.Such useful solid supports include but are not limited to nitrocelluloseand nylon. It is contemplated that such porous solid supports describedherein preferably are in the form of sheets of thickness from about 0.01to 0.5 mm, preferably about 0.1 mm. The pore size may vary within widelimits, and preferably is from about 0.025 to 15 microns, especiallyfrom about 0.15 to 15 microns. The surface of such supports may beactivated by chemical processes which cause covalent linkage of theantigen or antibody to the support. The irreversible binding of theantigen or antibody is obtained, however, in general, by adsorption onthe porous material by hydrophobic forces.

After the lysis mixture suspected of containing or containing theimmunosuppressant is brought into contact with the at least one firstcapture antibody, the resulting assay mixture is incubated to allow forthe formation of a first capture antibody (or multiple antibody)-drugcomplex. The incubation can be carried out at any suitable pH, includinga pH of from about 4.5 to about 10.0, at any suitable temperature,including from about 2° C. to about 45° C., and for a suitable timeperiod from at least about one (1) minute to about eighteen (18) hours,preferably from about 4-20 minutes, most preferably from about 17-19minutes.

After the addition of a detection agent and the formation of a labeledcomplex, the amount of label in the complex is quantified usingtechniques known in the art. For example, if an enzymatic label is used,the labeled complex is reacted with a substrate for the label that givesa quantifiable reaction such as the development of color. If the labelis a radioactive label, the label is quantified using a scintillationcounter. If the label is a fluorescent label, the label is quantified bystimulating the label with a light of one color (which is known as the“excitation wavelength”) and detecting another color (which is known asthe “emission wavelength”) that is emitted by the label in response tothe stimulation. If the label is a chemiluminescent label, the label isquantified detecting the light emitted either visually or by usingluminometers, x-ray film, high speed photographic film, a CCD camera,etc. Once the amount of the label in the complex has been quantified,the concentration of drug in the test sample can be determined by use ofa standard curve that has been generated, for example, using serialdilutions of immunosuppressant drug of known concentration. Other thanusing serial dilutions of the drug, the standard curve can be generatedgravimetrically, by mass spectroscopy and by other techniques known inthe art.

In a preferred forward competitive format, an aliquot of labeled drug,or analogue thereof, of a known concentration is used to compete withthe drug present in a test sample for binding to the antibody. In aforward competition assay, an immobilized antibody can either besequentially or simultaneously contacted with the test sample and alabeled drug or drug analogue thereof. The drug or drug analogue can belabeled with any suitable detectable label, including those detectablelabels discussed above. In this assay, the capture antibody can beimmobilized on to a solid support using the techniques discussedpreviously herein. Alternatively, the capture antibody can be coupled toan antibody, such as an antispecies antibody, that has been immobilizedon to a solid support, such as a microparticle.

The labeled drug or drug analogue, the lysis mixture and the antibodyare incubated under conditions similar to those described above inconnection with the sandwich assay format. Two different types ofantibody-drug complexes are then generated. Specifically, one of theantibody-drug complexes generated contains a detectable label while theother antibody-drug complex does not contain a detectable label. Theantibody-drug complex can be, but does not have to be, separated fromthe remainder of the assay mixture prior to quantification of thedetectable label. Regardless of whether the antibody-drug complex isseparated from the remainder of the assay mixture, the amount ofdetectable label in the antibody-drug complex is then quantified. Theconcentration of drug in the test sample can then be determined bycomparing the quantity of detectable label in the antibody-drug complexto a standard curve. The standard curve can be generated using serialdilutions of the drug of known concentration, by mass spectroscopy,gravimetrically and by other techniques known in the art.

The antibody-drug complex can be separated from the assay mixture bybinding the antibody to a solid support, such as the solid supportsdiscussed above in connection with the sandwich assay format, and thenremoving the remainder of the assay mixture from contact with the solidsupport.

In a reverse competition assay, an immobilized immunosuppressant drug oranalogue thereof can either be sequentially or simultaneously contactedwith a lysis mixture and at least one labeled antibody. The antibody canbe labeled with any suitable detectable label, including thosedetectable labels discussed above. The drug or drug analogue can bebound to a solid support, such as the solid supports discussed above inconnection with the sandwich assay format.

The immobilized drug or drug analogue, lysis mixture, and at least onelabeled antibody are incubated under conditions similar to thosedescribed above in connection with the sandwich assay format. Twodifferent types of antibody-drug complexes are then generated.Specifically, one of the antibody-drug complexes generated isimmobilized and contains a detectable label while the otherantibody-drug complex is not immobilized and contains a detectablelabel. The non-immobilized antibody-drug complex and the remainder ofthe assay mixture are removed from the presence of the immobilizedantibody-drug complex through techniques known in the art, such aswashing. Once the non-immobilized antibody-drug complex is removed, theamount of detectable label in the immobilized antibody-drug complex isthen quantified. The concentration of drug in the test sample can thenbe determined by comparing the quantity of detectable label in theantibody-drug complex to a standard curve. The standard curve can begenerated using serial dilutions of the drug of known concentration, bymass spectroscopy, gravimetrically and by other techniques known in theart.

In a fluorescence polarization assay, in one embodiment, an antibody orfunctionally active fragment thereof is first contacted with anunlabeled lysis mixture containing the immunosuppressant drug to form anunlabeled antibody-drug complex. The unlabeled antibody-drug complex isthen contacted with a fluorescently labeled drug or analogue thereof.The labeled drug or drug analogue competes with any unlabeled drug inthe assay mixture for binding to the antibody or functionally activefragment thereof. The amount of labeled antibody-drug complex formed isdetermined and the amount of drug in the test sample determined via useof a standard curve.

The use of scanning probe microscopy (SPM) for immunoassays also is atechnology to which the immunoassay methods of the present invention areeasily adaptable. In SPM, in particular in atomic force microscopy, acapture agent is affixed to a solid phase having a surface suitable forscanning. The capture agent can, for example, be adsorbed to a plasticor metal surface. Alternatively, the capture agent can be covalentlyattached to, e.g., derivatized plastic, metal, silicon, or glassaccording to methods known to those of ordinary skill in the art.Following attachment of the capture agent, the lysis mixture iscontacted with the solid phase, and a scanning probe microscope is usedto detect and quantify solid phase-affixed complexes. The use of SPMeliminates the need for labels which are typically employed inimmunoassay systems. Such a system is described in U.S. Pat. No.662,147, which is incorporated herein by reference.

Immunoassays according to the invention can also be carried out using aMicroElectroMechanical System (MEMS). MEMS are microscopic structuresintegrated onto silicon that combine mechanical, optical, and fluidicelements with electronics, allowing convenient detection of an analyteof interest. An exemplary MEMS device suitable for use in the inventionis the Protiveris' multicantilever array. This array is based onchemo-mechanical actuation of specially designed siliconmicrocantilevers and subsequent optical detection of the microcantileverdeflections. When coated on one side with a binding partner, amicrocantilever will bend when it is exposed to a solution containingthe complementary molecule. This bending is caused by the change in thesurface energy due to the binding event. Optical detection of the degreeof bending (deflection) allows measurement of the amount ofcomplementary molecule bound to the microcantilever.

In other embodiments, immunoassays according to the invention arecarried out using electrochemical detection. A basic procedure forelectrochemical detection has been described by Heineman and coworkers.This entailed immobilization of a primary antibody (Ab, rat-anti mouseIgG), followed by exposure to a sequence of solutions containing theantigen (Ag, mouse IgG), the secondary antibody conjugated to an enzymelabel (AP-Ab, rat anti mouse IgG and alkaline phosphatase), andp-aminophenyl phosphate (PAPP). The AP converts PAPP to p-aminophenol(PAP_(R), the “R” is intended to distinguish the reduced form from theoxidized form, PAP_(O), the quinoneimine), which is electrochemicallyreversible at potentials that do not interfere with reduction of oxygenand water at pH 9.0, where AP exhibits optimum activity. PAP_(R) doesnot cause electrode fouling, unlike phenol whose precursor,phenylphosphate, is often used as the enzyme substrate. Although PAP_(R)undergoes air and light oxidation, these are easily prevented on smallscales and short time frames. Picomole detection limits for PAP_(R) andfemtogram detection limits for IgG achieved in microelectrochemicalimmunoassays using PAPP volumes ranging from 20.mu.l to 360 μL have beenreported previously. In capillary immunoassays with electrochemicaldetection, the lowest detection limit reported thus far is 3000molecules of mouse IgG using a volume of 70 μL and a 30 min or 25 minassay time.

Various electrochemical detection systems are described in U.S. Pat.Nos. 7,045,364 (issued May 16, 2006; incorporated herein by reference),7,045,310 (issued May 16, 2006; incorporated herein by reference),6,887,714 (issued May 3, 2005; incorporated herein by reference),6,682,648 (issued Jan. 27, 2004; incorporated herein by reference);6,670,115 (issued Dec. 30, 2003; incorporated herein by reference).

In particular embodiments, useful, for example, for simultaneouslyassaying multiple analytes in one test sample, the solid phase caninclude a plurality different capture agents. Thus, for example, thesolid phase can have affixed thereon a plurality of antibodies, whereineach is intended to test for the presence of different analytes in thesample. In an exemplary embodiment, the solid phase can consist of aplurality of different regions on a surface, wherein each region has aparticular antibody affixed therein.

Multiplex formats can, but need not, employ a plurality of labels,wherein each label is used for the detection of a particular analyte.For example, multiple, different analytes can be detected without usinga plurality of labels where a plurality of capture agents, such asantibodies, are affixed to the solid phase at different known locations,based on specificity. Because the specificity of the capture agent ateach location is known, the detection of a signal at a particularlocation can be associated with the presence of analyte bound at thatlocation. Examples of this format include microfluidic devices andcapillary arrays, containing different capture agents at differentlocations along a channel or capillary, respectively, and microarrays,which typically contain different capture agents arranged in a matrix ofspots (“target elements”) on a surface of a solid support. In particularembodiments, each different capture agent can be affixed to a differentelectrode, which can, for example, be formed on a surface of a solidsupport, in a channel of a microfluidic device, or in a capillary.

III. Test Kits

The invention also provides test kits for assaying test samples for ananalyte. Test kits according to the invention include one or morereagents useful for practicing one or more immunoassays according to theinvention. A test kit generally includes a package with one or morecontainers holding the reagents, as one or more separate compositionsor, optionally, as admixture where the compatibility of the reagentswill allow. The test kit can also include other material(s), which maybe desirable from a user standpoint, such as a buffer(s), a diluent(s),a standard(s), and/or any other material useful in sample processing,washing, or conducting any other step of the assay.

In particular embodiments, test kits of the invention can include: (a)at least one antibody or protein capable of binding specifically to atleast one analyte; and (b) a lysis reagent comprising: a glycol selectedfrom the group consisting of ethylene glycol, propylene glycol, and ananalog thereof; and at least one alcohol having five or fewer carbons.In exemplary embodiments, useful for carrying out immunoassays forimmunosuppressant drugs, the antibody can be specific for rapamycin(sirolimus), tacrolimus, everolimus, temsorolimus, zotarolimus,cyclosporine, or analogs of any of these compounds.

In certain embodiments, the lysis reagent includes methanol, ethanol,propanol, or a mixture of any of these alcohols. In exemplaryembodiments, the ratio of glycol to alcohol is in the range of about 4:1to about 1:4, more particularly, in the range of about 4:1 to about 1:2.

If desired, the test kit can additionally include a control compositionthat includes the analyte being assayed.

In particular embodiments, test kits according to the invention caninclude one or more detergents and/or agents that release the analytefrom one or more binding proteins in the test sample. Suitabledetergents or detergent combinations include non-ionic detergents, suchas saponin, as described above. Suitable releasing agents include agentsthat compete with the analyte for binding to one or more bindingproteins, as described above, and proteases, which can be used todegrade binding proteins and liberate non-protein analytes. Exemplaryproteases include proteinase K, subtilisin, dispase, thermolysin,trypsin, ficin, bromelain, and combinations thereof. Any detergents orproteases provided in kits of the invention should be provided in amanner that facilitates the production of a lysis mixture containing thecomponents in suitable concentration, as described above.

Kits according to the invention can include a solid phase and a captureagent that is affixed to the solid phase or that becomes solidphase-affixed during the assay. In exemplary embodiments, the solidphase includes one or more microparticles or electrodes. Where such kitsare to be employed for conducting sandwich immunoassays, the kits canadditionally include a labeled detection agent. In certain embodiments,the test kit includes at least one direct label, such asacridinium-9-carboxamide. Test kits according to the invention can alsoinclude at least one indirect label. If the label employed generallyrequires an indicator reagent to produce a detectable signal, the testkit preferably includes one or more suitable indicator reagents.

Test kits according to the invention preferably include instructions forcarrying out one or more of the immunoassays of the invention.Instructions included in kits of the invention can be affixed topackaging material or can be included as a package insert. While theinstructions are typically written or printed materials they are notlimited to such. Any medium capable of storing such instructions andcommunicating them to an end user is contemplated by this invention.Such media include, but are not limited to, electronic storage media(e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g.,CD ROM), and the like. As used herein, the term “instructions” caninclude the address of an internet site that provides the instructions.

It is understood that the examples and embodiments described herein arefor illustrative purposes only and that various modifications or changesin light thereof will be suggested to persons skilled in the art and areto be included within the spirit and purview of this application andscope of the appended claims.

In addition, the commonly owned, co-pending application filed on Dec.29, 2006, entitled “Diagnostic Test For The Detection Of A Molecule OrDrug In Whole Blood” in the name(s) of Frank C. Grenier, Ryan F.Workman, Hina N. Syed, and Ali Salman (Attorney Docket No. ABOTP005) isexplicitly incorporated by reference in its entirely.

The commonly owned, co-pending application filed on Dec. 29, 2006,entitled “Non-Denaturing Lysis Reagent For Use With Capture-In-SolutionImmunoassay” in the name(s) of Shelley Holets-McCormack (Attorney DocketNo. ABOTP006) is explicitly incorporated by reference in its entirely.

The commonly owned, co-pending application filed on Dec. 29, 2006,entitled “Improved Assay For Immunosuppressant Drugs” in the name(s) ofSusan Drengler, and Wade Baugher (Attorney Docket No. ABOTP008) isexplicitly incorporated by reference in its entirely.

In addition, all other publications, patents, and patent applicationscited herein are hereby incorporated by reference in their entirety forall purposes.

EXAMPLES

The following examples are offered to illustrate, but not to limit, theclaimed invention.

Example 1 Lysis and Immunoassay of a Blood Sample for Sirolimus

This example illustrates the use of a non-denaturing lysis reagent tolyse a blood sample and carry out an automated immunoassay forsirolimus.

A lysis reagent is prepared by mixing propylene glycol and ethanol at avolume:volume ratio of 4:1. Lysis of a blood sample is accomplished bymixing 100 μL of sample with 200 μL of lysis reagent by vortexingvigorously for 5-10 seconds. Lysis is complete in less than 1 min atroom temperature. The resulting lysis mixture is assayed on an automatedARCHITECT i2000 analyzer (Abbott Laboratories, Abbott Park, Ill.) by:

(1) Mixing 10-40 uL of the lysis mixture with 50 uL of microparticlescoated with goat anti-mouse antibody (from Sigma, St. Louis, Mo.) andmouse anti-sirolimus antibody (prepared as described below).

(2) Incubating the assay mixture for approximately 18 minutes at 33-38degrees C. The sirolimus in the sample binds the anti-sirolimus antibodyon the microparticles.

(3) Adding 20 uL of acridinium-sirolimus conjugate to the reactionmixture.

(4) Incubating the reaction mixture for approximately 4 minutes at 33-38degrees C. The acridinium-sirolimus conjugate binds free anti-sirolimusbinding sites.

(5) Washing the microparticles with a phosphate buffer.

(6) Adding Pre-trigger (acid solution) and Trigger (basic solution) tocause the captured acridinium-sirolimus label to emit light, which ismeasured by the instrument.

The sirolimus binding antibody was produced as follows: Female RBf/Dnjmice were administered 3 monthly boosts of a sirolimus-27-CMO-tetanustoxoid immunogen, followed by an immunization withsirolimus-42-HS-tetanus toxoid preparation on the 4th month. Sevenmonths later, an intrasplenic pre-fusion boost was administered to theanimals using the sirolimus-27-CMO-tetanus toxoid immunogen 3 days priorto the fusion. Splenic B-cells were isolated and used in a standard PEGfusion with the SP2/0 myeloma. Confluent cultures were screened foranti-sirolimus activity 10-14 days later in a microtiter EIA, andpositive cultures were cloned using limiting dilution cloning technique.Isolated clones were scaled up in IMDM w/FBS (Invitrogen) tissue culturemedium, and secreted antibody was affinity purified using Protein A.

1-54. (canceled)
 55. A test kit comprising: (a) at least one antibody orprotein capable of binding specifically to at least one analyte; (b) alysis reagent comprising a glycol selected from the group consisting ofethylene glycol, propylene glycol, and an analog thereof; and (c) atleast one alcohol having five or fewer carbons for inclusion in thelysis reagent at a ratio of glycol to alcohol in the range of about 4:1to about 1:4, and, after addition of the alcohol, the lysis reagent is ahomogeneous mixture that is sufficiently free of large particulates toallow automated pipetting of the mixture, wherein the lysis reagent doesnot comprise detergent or a chelating agent and can be assayed withoutthe need for a separation step.
 56. The test kit of claim 55, whereinthe lysis reagent and alcohol(s) are combined and packaged in a singlecontainer.
 57. The test kit of claim 55, wherein the analyte comprisesan immunosuppressant drug.
 58. The test kit of claim 57, wherein theimmunosuppressant drug is selected from the group consisting ofsirolimus, tacrolimus, everolimus, temsorolimus, zotarolimus,cyclosporine, and analogs of any of these compounds.
 59. The test kit ofclaim 55, additionally comprising a control composition comprising theat least one analyte of (a).
 60. The test kit of claim 55, wherein thealcohol is selected from the group consisting of methanol, ethanol, andpropanol.
 61. The test kit of claim 55, wherein the ratio of glycol toalcohol is in the range of about 4:1 to about 1:2.
 62. The test kit ofclaim 55, wherein the test kit additionally comprises an agent thatreleases the analyte from one or more binding proteins in the testsample.
 63. The test kit claim 62, wherein the agent competes with theanalyte for binding to said one or more binding proteins.
 64. The testkit of 63, wherein the agent analyte is an immunosuppressant drug andthe agent comprises a different, but structurally similar,immunosuppressant drug.
 65. The test kit claim 62, wherein the agentcomprises a protease that degrades said one or more binding proteins.66. A test kit comprising: (a) at least one antibody or protein capableof binding specifically to at least one immunosuppressant drug selectedfrom the group consisting of sirolimus, tacrolimus, everolimus,temsorolimus, zotarolimus and cyclosporine; (b) a lysis reagentcomprising propylene glycol and ethanol at a ratio in the range of about4:1 to about 1:2, wherein the lysis reagent is a homogeneous mixturethat is sufficiently free of large particulates to allow automatedpipetting of the mixture, wherein the lysis reagent does not comprisedetergent or a chelating agent and can be assayed without the need for aseparation step; and (c) a control composition comprising the at leastone immunosuppressant drug of (a).
 67. The test kit of claim 66, whereinthe at least one immunosuppressant drug comprises sirolimus.
 68. A testkit comprising: (a) at least one antibody or protein capable of bindingspecifically to a non-protein analyte; and (b) a lysis reagentcomprising a glycol selected from the group consisting of ethyleneglycol, propylene glycol, and an analog thereof, and at least onealcohol having five or fewer carbons, wherein the glycol and the alcoholare mixed at a ratio in the range of about 4:1 to about 1:4, wherein thelysis reagent is a homogeneous mixture that is sufficiently free oflarge particulates to allow automated pipetting of the mixture, whereinthe lysis reagent does not comprise detergent and can be assayed withoutthe need for a separation step.
 69. The test kit of claim 68, whereinthe analyte comprises an immunosuppressant drug.
 70. The test kit ofclaim 69, wherein the immunosuppressant drug is selected from the groupconsisting of sirolimus, tacrolimus, everolimus, temsorolimus,zotarolimus, cyclosporine, and analogs of any of these compounds. 71.The test kit of claim 68, additionally comprising a control compositioncomprising the at least one analyte of (a).
 72. The test kit of claim68, wherein the alcohol is selected from the group consisting ofmethanol, ethanol, and propanol.
 73. The test kit of claim 68, whereinthe ratio of glycol to alcohol is in the range of about 4:1 to about1:2.
 74. The test kit of claim 68, wherein the test kit additionallycomprises an agent that releases the analyte from one or more bindingproteins in the test sample.
 75. The test kit claim 74, wherein theagent competes with the analyte for binding to said one or more bindingproteins.
 76. The test kit of 75, wherein the agent analyte is animmunosuppressant drug and the agent comprises a different, butstructurally similar, immunosuppressant drug.
 77. The test kit claim 74,wherein the agent comprises a protease that degrades said one or morebinding proteins.
 78. The test kit claim 68, wherein the lysis reagentdoes not comprise a chelating agent.